Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Androstenes
  • Androstenols / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • BRCA2 Protein / genetics*
  • Bone Neoplasms / secondary
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Grading
  • Phthalazines / therapeutic use
  • Piperazines / therapeutic use
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / genetics*

Substances

  • Androstenes
  • Androstenols
  • Antineoplastic Agents
  • BRCA2 Protein
  • BRCA2 protein, human
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • abiraterone
  • olaparib

Associated data

  • ClinicalTrials.gov/NCT00749502
  • ClinicalTrials.gov/NCT00777582